We wish to share that the DMPA-SC COF has completed its final funding cycle, and no new awards will be funded after the current cycle is complete. All applications currently under review will be processed as planned.

Over the past six years, the DMPA-SC COF has been recognized by Ministries of Health, partners, and donors as a vital part of the funding landscape for product introduction and scale-up. By requiring projects to align with government priorities, the fund helped ensure that product introductions were more effective, better integrated into broader health systems, and more likely to achieve lasting impact. At its closure, the DMPA-SC COF successfully awarded $11.8M to 25 partners across 20 countries, leaving a lasting impact that will continue to improve health outcomes for women and girls.

We would like to extend our heartfelt thanks to all Ministries of Health, partners, and applicants who have contributed towards advancing the goals of this COF. In particular, we are deeply grateful to the Gates Foundation and CIFF for its instrumental support and vision for this work.

Beginning in 2026, funding for critical activities to advance DMPA-SC self-injection scale-up will be available under the Advancing Injectable Markets for Sustainability (AIMS) project's AIMS Fund. In the interests of fostering sustainability and building capacity, the AIMS Fund will support local nonprofit organizations with funding to fill gaps that are impeding a country’s progression through the phases of market development for DMPA-SC self-injection. More information on this new funding stream will be available at FPoptions.org/AIMS-fund in the near future, and you can sign up here to be notified when application information is available.